SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $500.00K, a 25.00% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $500.00K, a 54.55% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $400.00K, a 100.00% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $1.10M, a 83.33% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $3.10M, a 72.22% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $1.80M, a 21.74% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $2.30M, a 25.81% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $3.10M, a 82.35% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-06 | $1.00M 10-Q · filed 2026-08-06 | $1.40M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-12 | $900.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.00M derived: sum of 3 quarters · filed 2026-05-12 | $2.40M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.50M derived: sum of 2 quarters · filed 2026-03-09 | $1.90M derived: sum of 3 quarters · filed 2026-08-06 | $3.10M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-14 | $1.50M derived: sum of 2 quarters · filed 2026-08-06 | $2.70M 10-Q · filed 2025-11-14 | $2.80M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-06 | $1.50M 10-Q · filed 2026-08-06 | $1.60M 10-Q · filed 2025-08-07 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.30M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-12 | $1.30M derived: sum of 2 quarters · filed 2026-05-12 | $1.90M derived: sum of 3 quarters · filed 2026-05-12 | $2.30M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $800.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.20M derived: sum of 3 quarters · filed 2026-03-09 | $1.80M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-14 | $633.00K 10-Q · filed 2024-11-06 | $1.00M derived: sum of 2 quarters · filed 2025-11-14 | $1.60M 10-Q · filed 2025-11-14 | $2.10M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-07 | $418.00K 10-Q · filed 2024-08-08 | $1.00M 10-Q · filed 2025-08-07 | $1.50M derived: sum of 3 quarters · filed 2025-08-07 | $2.24M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-09 | $700.00K 10-Q · filed 2024-05-20 | $1.10M derived: sum of 2 quarters · filed 2025-05-09 | $1.84M derived: sum of 3 quarters · filed 2025-05-09 | $2.29M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.24M derived: sum of 2 quarters · filed 2025-03-31 | $1.69M derived: sum of 3 quarters · filed 2025-03-31 | $2.30M 10-K · filed 2025-03-31 | $2.50M 10-K · filed 2024-03-29 | ||
| 2023-09-30 | $739.00K 10-Q · filed 2024-11-06 | $1.19M derived: sum of 2 quarters · filed 2024-11-06 | $1.80M 10-Q · filed 2024-11-06 | $3.59M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $453.00K 10-Q · filed 2024-08-08 | $595.00K 10-Q · filed 2023-08-21 | $1.10M 10-Q · filed 2024-08-08 | $1.20M 10-Q · filed 2023-08-21 | $2.85M derived: sum of 3 quarters · filed 2024-08-08 | $3.33M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-20 | $637.00K 10-Q · filed 2023-05-15 | $2.40M derived: sum of 2 quarters · filed 2024-05-20 | $2.88M derived: sum of 3 quarters · filed 2024-05-20 | $3.47M derived: sum of 4 quarters · filed 2024-05-20 | ||
| 2022-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.28M derived: sum of 2 quarters · filed 2024-03-29 | $2.87M derived: sum of 3 quarters · filed 2024-03-29 | $3.10M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $478.00K 10-Q · filed 2022-11-14 | $1.07M derived: sum of 2 quarters · filed 2023-08-21 | $1.30M 10-Q · filed 2022-11-14 | $2.28M derived: sum of 4 quarters · filed 2023-08-21 | |||
| 2022-06-30 | $595.00K 10-Q · filed 2023-08-21 | $1.30M 10-Q · filed 2023-08-21 | $1.80M derived: sum of 3 quarters · filed 2023-08-21 | $2.20M derived: sum of 4 quarters · filed 2023-08-21 | |||
| 2022-03-31 | $806.00K 10-Q · filed 2023-05-15 | $806.78K 10-Q · filed 2022-05-12 | $1.21M derived: sum of 2 quarters · filed 2023-05-15 | $1.60M derived: sum of 3 quarters · filed 2023-05-15 | $2.27M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | $795.00K derived: sum of 2 quarters · filed 2023-04-14 | $1.46M derived: sum of 3 quarters · filed 2023-04-14 | $1.70M 10-K · filed 2023-04-14 | |||
| 2021-09-30 | $395.00K 10-Q · filed 2022-11-14 | $1.06M derived: sum of 2 quarters · filed 2022-11-14 | $1.30M 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $668.00K 10-Q · filed 2022-08-10 | $900.00K 10-Q · filed 2022-08-10 | |||||
| 2021-03-31 | $207.78K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |